SMi Group's 8th annual BioBanking conference returns to London this June

1. www.bio-banking-event.com
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
@SMi Pharma
@SMiPharm
#smibiobanking
CONFIRMED CHAIR:
• Brian Thomson, Director and Clinical Lead, 100K
Genome Project, Nottingham Health Science
Biobank
FEATURED SPEAKERS:
• Christopher Perrett, Regulation Manager, Human
Tissue Authority
• Gareth Bicknell, Biobank Operations Manager,
Human Biomaterials Resource Centre
• Johanna Beekman, Head of Biosample
Management, Bayer Pharmaceuticals
• Jennifer Cheeseman-Janes, Senior Director,
Biobank & Translational Research Core, Duke
University Department of Surgery
• Peadar MacGabhann, Director, Biostor Ireland
• Aarno Palotie, Research Director, Finland Institute
for Molecular Medicine
• Joseph Pickrell, CEO, Gencove
2018 FEATURED HIGHLIGHTS:
• Discuss the advantages of using cloud-based
storage software in the management of
biosamples
• Define the scope of digital phenotyping and low-
pass sequencing and consider the benefits of
sample-linkage
• Hear the different perspectives of privately-owned
and government-funded biobanks on the impact
of the new data protection regulations
• Explore how adopting a platform-economy-based
approach to support scientific research by creating
a world-wide network is revolutionising drug
discovery
• Gain insight into the advances of population-based
genomics biobanks and the numerous applications
of Genome-Wide Association Studies (GWAS)
CONFERENCE: 13TH-14TH
JUNE
2018HOLIDAY INN KENSINGTON FORUM, LONDON, UK
Focus on Ethics and Biosample
Management
SMi presents their 8th conference on…
BioBanking
BOOK BY 28TH FEBRUARY AND SAVE £400
BOOK BY 29TH MARCH AND SAVE £200
BOOK BY 30TH APRIL AND SAVE £100

2. BioBanking
Day One | Wednesday 13th June 2018 www.bio-banking-event.com
8.30 Registration & Coffee
9.00 Chairman’s Opening Remarks
Brian Thomson, Director and Clinical Lead for 100K Genome
Project, Nottingham Health Science Biobank
GUIDELINES, SAFETY AND REGULATION OF BIOSAMPLES
OPENING ADDRESS
9.10 Scaling biobanks with low-pass sequencing and digital phenotyping
• Low-pass sequencing refers to a genome that is sequenced to a
depth under 10x. This type of data is useful to call germline single-
nucleotide pairs (SNPs), find structural variants and offers a very
complete ascertainment of shared variation
• Digital phenotyping is a multidisciplinary field of science, defined
as the “moment-by-moment quantification of the individual-
level human phenotype in situ using data from personal digital
devices,” with particular focus on smartphones
• Digital phenotyping offers two types of data: active data and
passive data. The former refers to data that requires active input
from the users to be generated, whereas passive data, such as
sensor data and phone usage patterns, are collected without
requiring any active participation from the user
• Smartphone data can be used to study behavioural patterns,
social interactions, physical mobility, gross motor activity, and
speech production, among others. Ownership has been in steady
rise globally over the past years
Joseph Pickrell, CEO, Gencove
9.50 ISO 20387 – A new international standard for biobanking
• The importance of international minimum standards in enabling
resource interoperability and enhanced quality of scientific
results
• An introduction to the purpose, content, and limitations of ISO
20387
• What next? Moving forward from the horizontal standard
Gareth Bicknell, Biobank Operations Manager, Human Biomaterials
Resource Centre
10.30 Morning Coffee
11.00 Initiatives and strategies of ESBB: Advances in the field of
biobanking and relevant case studies
• The Principles of ESBB: Biobanking involves the ethical supply
of biosamples for research. Exploring how the definition had
developed through the years
• The goal is to identify problems in the biobanking field and
provide solutions and encourage high professional standards in
biobanking
• The society is meant to provide a strong united voice for
biobankers in the region, to influence development of their
field by encouraging and supporting public-private biobank-
related partnerships because of their scientific, medical and
commercial importance
• A systematic approach to consistency across databases.
Why we treasure a common language, and, talking from
experience, the potential advantages and disadvantages of
harmonisation
Balwir Matharoo-Ball, Deputy Director, Nottingham Health Science
Biobank, President, ESBB
11.40 UK biobanks: Ethics and regulations
• Ethical approval of UK biobanks: The role of the Health Research
Authority (HRA)
• Regulation of UK biobanks: The role of the Human Tissue
Authority (HTA)
Christopher Perrett, Regulation Manager, Human Tissue Authority
12.20 Networking Lunch
1.20 Generating high quality biological samples for high quality
research
• Sample linkage – establishing accurate linkage of patient and
sample data
• Sample logistics – maintaining sample integrity during
transportation
• Sample processing – the importance of sample and data
tracking during processing tasks
• Sample storage – creating accurate sample traceability during
storage and retrieval activities
• LIMS – a fundamental prerequisite to successful sample and
data traceability
Kristian Spreckley, Business Development Director, UK Biobank/ UK
Biocentre
BIOBANKING IN TRANSLATIONAL RESEARCH
2.00 Genome-Wide Association Studies: Generation Scotland and
VIKING Cohorts
• Genome-Wide Association Studies (GWAS) of health-related
measures and markers of genetic risk
• NHS electronic health record (EHR) and genomics analyses in
consented populations
• Governing biobanks: data and sample sharing and managed
access
• Are smaller biobanks still useful (and sustainable) in the era of
500,000 plus cohorts?
Shona Kerr, Project Manager, Institute of Genetics and Molecular
Medicine
2.40 Afternoon Tea
3.10 Adopting a platform economy based approach to support
scientific research by gathering biobanks and other health care
and genomic data providers in a worldwide network
• Digital platforms are the most effective business models for
future economies and societies where open data, high value
creation with new innovations and the network effects form the
basis of the activities
• Still, the biggest healthcare challenges today is to manage,
analyse, and interpret the growing amount of complex
genomic and other omics as well as the other health related
data in a systematic and secure manner
• Due to this, the digital platform (RQUEST) between the data
producers (biobanks, hospitals and national data driven
initiatives) and users (pharma industry and academic research
groups) to revolutionise research and development by providing
a marketplace and network for turning health related real-world
data into real-world evidence needs to be adopted
Heli Salminen-Mankonen, Research Director, Digital Futures,
University of Turku
3.50 FIMM: A long-term disease association national project
• Further development of linkage to health-related datasets
(i.e. for primary care as well as for death, cancer and
hospitalisation)
• Further development of outcome adjudication processes (i.e.
scalable approaches for large number and range of outcomes)
• Further development of data storage and access systems, and
maintenance/development of the sample archives
• Complete ongoing funded enhancements: genotyping (and
telomere assays), biochemical assays and imaging assessments.
Aarno Palotie, Research Director, Finland Institute for Molecular
Medicine
4.30 Chairman’s Closing Remarks and Close of Day One
Register online at www.bio-banking-event.com
SUPPORTED BY
SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy. Prime
networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your
industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call:
Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk

3. BioBanking
www.bio-banking-event.com Day Two | Thursday 14th June 2018
8.30 Registration & Coffee
9.00 Chairman’s Opening Remarks
Brian Thomson, Director and Clinical Lead for 100K Genome
Project, Nottingham Health Science Biobank
TECHNOLOGY UPDATES AND SAMPLE MANAGEMENT
OPENING ADDRESS
9.10 INFANT – Translational Research, Stem Cell-based products and
customised workflows for biobanks
• Managing the lifecycle of clinical assets to better enable
advancements in translational research - working to currently
accepted best practices: ISBER, OECD and MMI guidelines
• Why is it crucial to the efficiency of manufacture and the
efficacy of cell therapies?
• How: Careful monitoring, procedural controls and novel
technologies
• Creating customised workflows for biobanks which are split
across continents in multi-centred studies
• New cell and tissue types are required for therapy, and will need
new technological and scientific developments
Emma Snapes, Biobank Manager, INFANT - Irish Centre for Foetal
and Neonatal Translational Research
9.50 Design & qualification of a cloud based biosample information
management system
• Workflow process mapping and user requirements specification
• GDPR requirements
• System qualification and validation
• Ethics and consent and open science cloud
Paedar MacGabhann, Director, Biostor Ireland
10.30 Morning Coffee
11.00 A Collaboration between UK Biobank, GSK and Regeneron in the
creation of the World’s largest Gene Sequencing initiative
• Generation of genetic sequence data from the health
database’s of 500,000 volunteer participants, intended to help
researchers collect genetic evidence for use in developing new
treatments against a wide range of diseases
• Sequencing focused specifically on the 1% to 2% of the genome
known as the exome, or the protein encoding regions of the
genome, which is believed to have the most relevance for drug
therapy
• UK Biobank has collected health, lifestyle, medical, and
biological data from participants for 10 years. The costs of
gene sequencing are falling, but doing it on a large scale
involves highly specialized capabilities and is expensive—with
an estimated cost of $150 million if all 500,000 participants are
sequenced
Speaker to be confirmed
BIOBANKING: APPLICATIONS IN THE INDUSTY
11.40 Bayer’s concept of two biobanks in Research & Development
• Providing our research departments with high quality biological
specimens for the purpose of target identification and
validation, biomarker assay development and validation and
develop of companion diagnostics (Bayer’s Research Biobank)
• Enabling the optimal use of biological specimens collected in
Bayer’s global clinical trials for the thorough investigation of
the product and the treated disease (Bayer’s Clinical Sample
Repository)
• Ensuring that these biological specimens are collected
according to the appropriate guidelines, ethical standards and
ensuring high standards of data privacy.
• Linking the biological specimens and generated biomarker
data with the corresponding clinical data through an innovative
platform
Johanna Beekman, Head of Biosample Management, Bayer
Pharmaceuticals
12.20 Networking Lunch
1.20 Biobanking in the future: Challenges & opportunities
• Biobanking at Medical University of Graz
• Developments in biobanking - The last 10 years
• Automation
• Challenges & Opportunities
Karine Sargsyan, Biobank Managing Director, Medical University
of Graz
2.00 Banking of clinical grade human Pluripotent Stem Cells
• The UK Stem Cell Bank is a key partner of the UK regenerative
medicine infrastructure, charged with procuring, processing and
distributing seed stocks of human embryonic stem cell lines for
research and clinical application
• One of the key objectives of the UKSCB is to bank and release
stem cell lines that meet the EU Tissue and Cell Directives
(EUTCD) criteria as set out in Human Tissue Authority regulations
• 38 ethically sourced human embryonic stem cell lines have
been approved for deposit as EUTCD-Grade by the UK Steering
Committee, and over 10 lines have been banked on feeders
are already available from the UK Stem Cell Bank
• The UK Stem Cell Bank is currently focusing its activities on
supplying feeder-free deeply characterised EUTCD-grade
human embryonic stem cell lines, to support the regenerative
medicine community in the development of quality and safety-
assured cell therapies
Sofia Spyrou, Production Manager, UK Stem Cell Bank
2.40 Afternoon Tea
3.10 Long-term biobanking: How long can you hold samples?
• The amount of biological material requiring storage increases, it
is therefore vital to be able to accurately log and store samples
in a robust, inert environment ensuring sample integrity. The
ability to select and retrieve only the samples required, limiting
any potential freeze-thawing of unselected samples is now a
standard requirement in the biomedical research industry today
• In order to prevent a loss of integrity among samples experts
involved in the collection and storage of biospecimens must
follow certain practices. These procedures should be based
on up-to-date, relevant research studies that demonstrate the
most effective methods for storing specimens, as well as the
maximum length of time they can be stored safely
• Small, high density, automated biobanking stores have become
important to manage sample storage effectively in a limited
space. Examples include: urine, hair, DNA and antibodies
• For long-term biobanking, understanding your sample’s
limitations is essential. Some of the information provided should
be used as a guide to determine the best practices for storing
your samples so that you can maximize their shelf life and ensure
that they are viable when you need them
Jennifer Cheeseman-Janes, Senior Director, Biobank and
Translational Research Core, Duke University Department of Surgery
3.50 Stratified medicine and biobank integration in hospital routine
• Stratified medicine is based on identifying subgroups of patients
with distinct mechanisms of disease, or particular responses
to treatments, with the aim of us to identify and develop
treatments that are effective for particular groups of patients
• A biobank as a repository of biological specimens and linked
clinical data has the potential to provide an ideal knowledge
and data platform for the delivery of stratified and personalised
medicine
• In order to do fulfil this key role so Biobanks will be required to
navigate stringent governance, ethical and logistic barriers to
full integration with clinical services
• A strategy for doing so will be discussed
Brian Thomson, Director and Clinical Lead for 100K Genome
Project, Nottingham Health Science Biobank
4.30 Chairman’s Closing Remarks and Close of Day Two
Alternatively fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
SUPPORTED BY
Want to know how you can get involved? Interested in promoting your services to this market?
Contact Alan Caddick, SMi Marketing on +44 (0) 20 7827 6038 or
email: acaddick@smi-online.co.uk

4. Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
BIOBANKING
Conference: 13th -14th June 2018, Holiday Inn Kensington Forum, London, UK
4 WAYS TO REGISTER
FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
ONLINE at www.bio-banking-event.com
POST your booking form to: Events Team, SMi Group Ltd,
1 Westminster Bridge Road, London, SE1 7XW
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk
Payment: If payment is not made at the time of booking, then an invoice will be issued and must
be paid immediately and prior to the start of the event. If payment has not been received then
credit card details will be requested and payment taken before entry to the event. Bookings within
7 days of event require payment on booking. Access to the Document Portal will not be given until
payment has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send
a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge,
providing that cancellation is made in writing and received at least 28 days prior to the start of the
event. Regretfully cancellation after this time cannot be accepted. We will however provide the
conferences documentation via the Document Portal to any delegate who has paid but is unable
to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to
provide documentation in these circumstances. We cannot accept cancellations of orders placed
for Documentation or the Document Portal as these are reproduced specifically to order. If we
have to cancel the event for any reason, then we will make a full refund immediately, but disclaim
any further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection
Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about
other products and services. Unless you tick here □ we may also share your data with third parties
offering complementary products or services. If you have any queries or want to update any of the
data that we hold then please contact our Database Manager databasemanager@smi-online.
co.uk or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your
address on the attached letter.
Unique Reference Number
Our Reference P-256
Terms and Conditions of Booking
DELEGATE DETAILS
Payment must be made to SMi Group Ltd, and received before the event, by one of
the following methods quoting reference P-256 and the delegate’s name. Bookings
made within 7 days of the event require payment on booking, methods of payment:
□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
□ Credit Card □ Visa □ MasterCard □ American Express
SMi Group will apply surcharges to commercial cards
Please tick here □ if the card provided is not a commercial card
Card No: □□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
Card Billing Address (If different from above):
DOCUMENTATION
I cannot attend but would like to Purchase access to the following Document Portal/
Paper Copy documentation. Price Total
□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations – paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
PAYMENT
VAT
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged
on Document portal and literature distribution for all UK customers and for those EU
Customers not supplying a registration number for their own country here
CONFERENCE PRICES GROUP DISCOUNTS AVAILABLE
I would like to attend: (Please tick as appropriate) Fee TOTAL
□ Conference only £1499.00 + VAT £1798.80
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80
The conference fee includes refreshments, lunch, conference papers, and access to
the Document Portal. Presentations that are available for download will be subject
to distribution rights by speakers. Please note that some presentations may not be
available for download. Access information for the document portal will be sent to
the e-mail address provided during registration. Details are sent within 24 hours post
conference.
VENUE Holiday Inn Kensington Forum, 97 Cromwell Road, London SW7 4DN
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: events@smi-online.co.uk or fax +44 (0) 870 9090 712
□ Book by 28th February to receive £400 off the conference price
□ Book by 29th March to receive £200 off the conference price
□ Book by 30th April to receive £100 off the conference price
EARLY BIRD
DISCOUNT